Globeflex Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Globeflex Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,719	Closed	-$493K	–	402
2026 Q1	$493K	Hold	8,719	–	–	0.07%	228
2025 Q4	$518K	Hold	8,719	–	–	0.08%	242
2025 Q3	$472K	Buy	8,719 +6,813	+357%	+$390K	0.07%	250
2025 Q2	$105K	Hold	1,906	–	–	0.01%	370
2025 Q1	$135K	Buy	+1,906	New	+$128K	0.01%	349
2022 Q4	–	Sell	-1,164	Closed	-$99K	–	482
2022 Q3	$99K	Buy	+1,164	New	+$104K	0.02%	398
2022 Q2	–	Sell	-1,462	Closed	-$113K	–	486
2022 Q1	$113K	Buy	+1,462	New	+$122K	0.02%	393
2015 Q3	–	Sell	-4,200	Closed	-$574K	–	503
2015 Q2	$574K	Hold	4,200	–	–	0.11%	294
2015 Q1	$523K	Sell	4,200 -7,840	-65%	-$831K	0.1%	286
2014 Q4	$1.09M	Sell	12,040 -25,900	-68%	-$2.15M	0.21%	201
2014 Q3	$2.74M	Buy	37,940 +34,140	+898%	+$2.24M	0.31%	114
2014 Q2	$236K	Buy	+3,800	New	+$230K	0.03%	342

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Globeflex Capital's BMRN Position: Q2 2026 in Review

Globeflex Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 8,719 shares — an estimated $493K sold.

Globeflex Capital first reported a position in BMRN in Q2 2014 and held it in 12 quarters. The position peaked at $2.74M in Q3 2014. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Globeflex Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Globeflex Capital sold 8,719 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $493K.
Globeflex Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 12 quarters.
Globeflex Capital's BioMarin Pharmaceuticals position peaked at $2.74M in Q3 2014.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.